Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region
Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC. For metastatic BC (mBC), standard therapy options...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Shiraz University of Medical Sciences
2025-10-01
|
| Collection: | Middle East Journal of Cancer |
| Sujets: | |
| Accès en ligne: | https://mejc.sums.ac.ir/article_50590_31ce17421f15ccce87c42b6fa6221037.pdf |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|